Most of the pain that arises from malignant disease can be well managed with oral opioids. A small percentage of patients with cancer, however, have opioid-insensitive pain. This type of pain, whether it be nociceptive or neuropathic, may be suitable for control by central neuraxis blockade with a local anaesthetic/morphine combination. This is the report of a patient with adenocarcinoma of the anus managed successfully over a 49-week period with an intermittent infusion of bupivacaine and morphine using a multiprogrammable, totally implanted infusion pump.
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CASE REPORT
A 60-year-old man was referred for help in managing intractable pain from an ulcerating adenocarcinoma of the anus. The patient had been diagnosed nine months previously and had secondary deposits in the inguinal lymph node system. The patient had elected not to proceed with surgery and external beam radiotherapy had been instituted.
On presentation at the Pain Management Clinic, the patient was experiencing severe perianal and buttock pain which prevented him from sitting. In the perianal area he had two five-centimetre ulcers with deep induration which were exquisitely painful. There was marked scrotal and inguinal oedema; however, he had some control over his bladder and could urinate with manual pressure over the lower abdomen. Defaecation was very painful. He was otherwise well and reasonably mobile. Computerised tomography of the pelvis and abdomen showed no pelvic, liver or abdominal spread. Chest X-ray was normal. He was receiving oral morphine 125 mg four-hourly and topical lignocaine gel to the ulcers. He was experiencing unpleasant drowsiness with little analgesia from this dose of morphine. It was anticipated that his life expectancy might be one year.
Initial management included an intrathecal injection of 5070 phenol in glycerine. An incremental injection in the sitting position to 3 ml gave good pain relief which lasted for one week. The injection was repeated but only six days of moderate pain relief was experienced. A temporary tunnelled intrathecal catheter (18 gauge Portex) was then placed and heavy lignocaine 25 mg (Xylocaine 5070 Heavy, Astra Pharmaceuticals) with morphine 2.5 mg (Morphine Sulphate, David Bull Laboratories) gave good analgesia for four hours with a motor block which lasted for 30 to 40 minutes. A defunctioning colostomy was performed and a urethral catheter was placed. Over the next three days intermittent boluses of lignocaine 25 mg and morphine 2.5 mg were given. However, the duration of analgesia between injections decreased, and consequently the frequency of injections increased. A change to bupivacaine 2.5 mg with morphine 2 mg was made and this was administered four-hourly. The patient remained mobile, apart from 30 minutes after each bolus when he experienced marked quadriceps weakness. He was pain-free and all oral morphine was stopped.
The temporary percutaneous intrathecal catheter was removed and a Synchromed Infusion Pump (Medtronic Pty Ltd) was placed in a subcutaneous pouch in the abdominal wall. This was connected to an intrathecal silicone catheter inserted at the L2-3 interspace and fed caudally.
The pump was externally programmed using a radiowave telemetry link and set to deliver a bolus of 0.5 ml of a solution containing 0.47070 bupivacaine with morphine 1.6 mg/ml every four hours. As the pump reservoir had a capacity of 18 ml it was necessary to refill it every six days. This was arranged with the Hospice Home Care Nursing Service.
On this regimen he was stable, mobile and pain-free for the next four months. However, during this time he developed further perineal, scrotal and inguinal ulceration and gradually became weaker. During the subsequent four months it was necessary to decrease the interval between boluses to three hours. He could sit and was mobile in a wheelchair. He had no drowsi-Anaesthesia and Intensive Care, Vol. 21, No. 2, April, 1993 ness and still maintained an active part in his family life. During the final three months of his life he required 0.75-1.00 ml boluses of the same solution every two hours to control his pain. He died of cachexia 345 days following the institution of intrathecal therapy.
DISCUSSION
Opioid-insensitive pain of malignancy is often difficult to treat. The debate about the degree of sensitivity of different types of chronic pain to morphine continues. It is seemingly not an all-or-none response. I High-dose systemic morphine does not always relieve pain, yet can cause nausea, drowsiness, constipation, dryness of the mouth, dysaesthesia and occasionally myoclonic jerks. A range of membranestabilising drugs such as carbamazepine, sodium valproate, mexiletine and flecainide, despite their sideeffects, have been found to be useful, but were not particularly so for our patient. 2 Tricyclic antidepressants are also of value for neuropathic pain, sleeplessness and depression. 3 Intrathecal management of cancer pain is not new and large series have been reported. 4 ,5 The technology to safely administer chronic infusions into the intrathecal space is now available. Neurotoxicity tests on medium-to long-term bupivacaine infusions suggest that the catheter systems and the drug are safe. 6 ,7 A recent report, however, has described problems in patients with underlying arachnoiditis. 8 The addition of opioids to intraspinal local anaesthetics appears to improve the quality of analgesia 9 and this may be a supraspinal effect. 10 The initial, apparent acute tolerance to lignocaine was not seen with bolus qosing of bupivacaine/ morphine; however, dose requirements did escalate, presumably in part due to disease progression, but at a slower pace.
Infection always remains a concern with intrathecal therapy but it appears to be uncommon. 4, 5 Initial access to the pump refill port was required every six days; towards the end of our patient's life this increased to every second day. The observance of strict asepsis at refill and the 0.2 micron filter in the fluid path should minimise this risk.
In patients with a life expectancy in excess of six months, where it can be shown by percutaneous trial that intrathecal therapy is effective, consideration could be given to an implantable drug delivery system.
